IP Library Granted Patent US 9,109,261
Granted Patent B2
US 9,109,261 · App. 12/774,229 · Granted Aug 18, 2015

Method and kit for identifying antibiotic-resistant microorganisms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,109,261
App. No.
12/774,229
Granted
Aug 18, 2015
Kind
B2
Abstract

The invention provides a rapid sample-processing method for preparing hybridization reaction mixtures substantially depleted of RNA, and a method of identifying the methicillin-resistance status and vancomycin-resistance status of an organism.

Claims (24)

1. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising a solid support and a plurality of detectably labeled solution-phase hybridization probes distributed among a plurality of loci thereon, said plurality of loci comprising,

(a) a first locus that comprises one or more solution-phase hybridization probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of bacteria in the genus Staphylococcus , comprising Staphylococcus aureus and Staphylococcus epidermidis , but do not hybridize to ribosomal nucleic acids of bacteria in the genus Enterococcus ,

(b) a second locus that comprises a probe mix containing

(i) one or more solution-phase hybridization probes that collectively hybridize to ribosomal nucleic acids from a plurality of bacteria in the genus Enterococcus , comprising Enterococcus faecalis and Enterococcus faecium , but not Staphylococcus aureus or any other bacteria in the genus Staphylococcus , and

(ii) at least one solution-phase hybridization probe that hybridizes to ribosomal nucleic acids from Staphylococcus aureus but not from other species in the genus Staphylococcus or bacteria in the genus Enterococcus ,

(c) a third locus that comprises a probe mix containing a first mecA solution-phase hybridization probe that consists of the nucleotide sequence of SEQ ID NO:2 or the complement thereof, a second mecA solution-phase hybridization probe that consists of the nucleotide sequence of SEQ ID NO:3 or the complement thereof, and a third mecA solution-phase hybridization probe that consists of the nucleotide sequence of SEQ ID NO:5 or the complement thereof, and

(d) a fourth locus that comprises a solution-phase hybridization probe that hybridizes both to VanA nucleic acids and VanB nucleic acids, wherein said solution-phase hybridization probe consists of the nucleotide sequence of SEQ ID NO:33 or the complement thereof; wherein each of said plurality of loci is configured as a matrix that provides an identification of one or more unknown nucleic acids from a sample, and wherein each of said detectably labeled solution-phase hybridization probes comprises a polynucleotide sequence which is covalently attached to a non-nucleotide detectable moiety that emits a detectable signal.

2. The device of claim 1 , wherein said non-nucleotide detectable moiety is a homogeneously detectable label.

3. The device of claim 2 , wherein said homogeneously detectable label is a chemiluminescent label.

4. The device of claim 1 , further comprising a fifth locus, said fifth locus comprising one or more solution-phase hybridization probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of Gram-positive bacteria comprising the high(G+C) subset thereof, a plurality of species of bacteria in the family Enterobacteriaceae , a plurality of species of bacteria in the genus Enterococcus , and a plurality of species of bacteria in the genus Staphylococcus .

5. The device of claim 1 , wherein the first mecA solution-phase hybridization probe of said probe mix consists of the nucleotide sequence of SEQ ID NO:2, wherein the second mecA solution-phase hybridization probe of said probe mix consists of the nucleotide sequence of SEQ ID NO:3, and wherein the third mecA solution-phase hybridization probe of said probe mix consists of the nucleotide sequence of SEQ ID NO:5.

6. The device of claim 1 , wherein each of said plurality of detectably labeled solution-phase hybridization probes comprises the non-nucleotide detectable moiety prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

7. The device of claim 1 , wherein said plurality of loci are wells of a multi-well plate.

8. A kit for differentiating between bacteria, wherein said kit comprises the device of claim 1 .

9. The kit of claim 8 , wherein said kit comprises one or more of, a specimen lysis reagent; a probe hybridization reagent; a selection reagent; an alkaline hydrolysis reagent; or an internal control nucleic acid.

10. A device for detecting nucleic acids encoding resistance to an antibiotic, comprising a solid support and a plurality of detectably labeled solution-phase hybridization probes distributed among a plurality of loci thereon, said plurality of loci comprising,

(a) a first locus that comprises one or more solution-phase hybridization probes that collectively hybridize to ribosomal nucleic acids from a plurality of bacteria in the genus Enterococcus , comprising Enterococcus faecalis and Enterococcus faecium,

(b) a second locus that comprises a solution-phase hybridization probe that hybridizes to both VanA nucleic acids and to VanB nucleic acids, wherein said solution-phase hybridization probe consists of the nucleotide sequence of SEQ ID NO:33 or the complement thereof, and

(c) a third locus that comprises one or more solution-phase hybridization probes that collectively hybridize to ribosomal nucleic acids from a plurality of species of Gram-positive bacteria comprising the high (G+C) subset thereof, a plurality of species of bacteria in the family Enterobacteriaceae , a plurality of species of bacteria in the genus Enterococcus , and a plurality of species of bacteria in the genus Staphylococcus; wherein each of said plurality of loci is arranged as a matrix for identification of one or more soluble unknown nucleic acids from a sample, and wherein each of said detectably labeled solution-phase hybridization probes comprises a polynucleotide sequence which is covalently attached to a non-nucleotide detectable moiety that emits a detectable signal.

11. The device of claim 10 , wherein said one or more solution-phase hybridization probes of said third locus comprise a pan-bacterial probe of SEQ ID NO:16.

12. The device of claim 10 , wherein each of said plurality of detectably labeled solution-phase hybridization probes comprises the non-nucleotide detectable moiety prior to contact with a biological sample to be tested for the presence of microorganisms or nucleic acids thereof.

13. The device of claim 10 , wherein said plurality of loci are wells of a multi-well plate.

14. A kit for differentiating between bacteria, wherein said kit comprises the device of claim 10 .

15. The kit of claim 14 , wherein said kit comprises one or more of, a specimen lysis reagent; a probe hybridization reagent; a selection reagent; an alkaline hydrolysis reagent; or an internal control nucleic acid.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2011
From: HOGAN, JAMES J.; KAPLAN, SHANNON K.
To: GEN-PROBE INCORPORATED
Reel/Frame 026030/0534 →